Actively Recruiting
Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study
Led by Casa di Cura San Raffaele Cassino · Updated on 2024-09-19
600
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
C
Casa di Cura San Raffaele Cassino
Lead Sponsor
I
IRCCS San Raffaele Roma
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying neurodegenerative diseases to find new early markers for diagnosis and prognosis. This prospective, observational, longitudinal study collects data from patients with conditions like Parkinson's Disease, Lewy Body Dementia, Alzheimer's Disease, and other movement or cognitive disorders. The goal is to improve early diagnosis and predict disease progression using clinical evaluations and advanced tools including artificial intelligence (AI). Participants undergo routine clinical examinations over 1 to 10 years. Data collected includes movement analysis with motion capture and wearable sensors, brain imaging, neuropsychological and electroencephalographic assessments, and blood chemistry tests. The study also explores AI-powered methods such as voice analysis and handwriting analysis using commercial devices, aiming to support remote diagnosis and monitoring. During the study, participants will be followed with regular clinical visits where various tests and assessments are performed. Researchers will monitor changes in motor and cognitive functions, analyze brain and blood markers, and use AI models to predict disease course. The study plans to track participants for up to 10 years to better understand progression and improve treatment strategies.
CONDITIONS
Brief Title
Neurodegenerative Diseases Progression Markers (MARKERS-NDD)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with Parkinson's Disease according to UK Parkinson's Disease Society Brain Bank criteria
- Patients diagnosed with Movement Disorders such as Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor
- Patients with cognitive impairment or dementia including probable Lewy Body Dementia, Alzheimer's Disease, Mild Cognitive Decline, or subjective memory complaints
- Willingness and ability to participate in the study and provide informed consent
You will not qualify if you...
- No restrictions based on age, disease severity, or cognitive impairment as long as the participant can complete research assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 to 10 years
Participants who undergo routine care are observed through clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests, and other routine examinations as part of normal clinical practice.
Visits scheduled according to routine clinical practice over the study duration
Trial Site Locations
Total: 1 location
1
San Raffaele Cassino
Cassino, Frosinone, Italy, 03043
Actively Recruiting
Research Team
M
Maria Francesca De Pandis, MD, PhD, Neurologist
M
Maria Gaglione
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here